Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances

Introduction: Acute lymphoblastic leukemia (ALL) is the first neoplasm where the assessment of early response to therapy by minimal residual disease (MRD) monitoring has proven to be a fundamental tool to guide therapeutic choices. The most standardized methods to study MRD in ALL are multi-parametr...

Descripción completa

Detalles Bibliográficos
Autores principales: Della Starza, Irene, Chiaretti, Sabina, De Propris, Maria S., Elia, Loredana, Cavalli, Marzia, De Novi, Lucia A., Soscia, Roberta, Messina, Monica, Vitale, Antonella, Guarini, Anna, Foà, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692455/
https://www.ncbi.nlm.nih.gov/pubmed/31448230
http://dx.doi.org/10.3389/fonc.2019.00726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692455/
https://www.ncbi.nlm.nih.gov/pubmed/31448230
http://dx.doi.org/10.3389/fonc.2019.00726

Ejemplares similares